NCT04187404

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

TERMINATEDPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2020-07-23Est. Completion: 2024-10-02

Enrollment target: 70 participants

Locations

MD Anderson Cancer Center, Houston, Texas, United States
Rigshospitalet, Copenhagen, Denmark
Chu Lille, Lille, France
Centre Léon Bérard, Lyon, France
Assistance Publique - Hôpitaux de Marseille - Hôpital Nord, Marseille, France
Institut Gustave Roussy, Villejuif, France
Lmu Klinikum, München, Germany
Universitätsklinikum Würzburg, Würzburg, Germany
Azienda Ospedaliera Spedali Civili, Brescia, Italy
Amsterdam UMC, location VUmc, Amsterdam, Netherlands
Hospital Universitari Vall d'Hebron, Barcelona, Spain
Karolinska University Hospital, Stockholm, Sweden

Other microbiome trials you might be interested in

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical CarcinomaPhase 1Recruiting

Adrenocortical Carcinoma (ACC)Recurrent Adrenocortical Carcinoma (ACC)Recurrent Abdominal Adrenocortical Carcinoma (ACC)Carcinoma, AdrenocorticalCarcinoma, Adrenal Cortical

Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are r…

Bethesda, United StatesEst. completion Dec 1, 2030

View Trial →

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyPhase 1Recruiting

Colorectal NeoplasmsNeoplasmsIntrahepatic Cholangiocarcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.